These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6421424)

  • 21. [Long-term therapy with human insulin. Clinical experiences].
    Sachse G; Mäser E; Federlin K
    Dtsch Med Wochenschr; 1985 Mar; 110(11):403-6. PubMed ID: 3884307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of human ultralente as the basal insulin component in treatment of patients with IDDM.
    Freeman SL; O'Brien PC; Rizza RA
    Diabetes Res Clin Pract; 1991 Jul; 12(3):187-92. PubMed ID: 1889348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two ultralente insulin preparations with protamine zinc insulin in clinically normal cats.
    Broussard JD; Peterson ME
    Am J Vet Res; 1994 Jan; 55(1):127-31. PubMed ID: 8141485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immunogenic properties of highly purified insulin preparations: The clinical importance of insulin-binding antibodies.
    Anderson OO
    Acta Endocrinol (Copenh); 1975 Apr; 78(4):723-35. PubMed ID: 1173962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
    Owens DR; Matfin G; Monnier L
    Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of insulin antibody levels during the first 3 years of treatment of adult diabetics with monocomponent porcine lente-insulin and single peak beef NPH insulin.
    Wajchenberg BL; Thomsen YG; Toledo e Souza IT; Germek OA
    Horm Metab Res; 1986 Aug; 18(8):535-9. PubMed ID: 3758926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A controlled study of prolonged study with semi-synthetic human insulin.
    Drury R; Keenan P; McEvoy M; Cregan D; Drury MI; Reeves WG
    Ir J Med Sci; 1983 Dec; 152(12):430-4. PubMed ID: 6365832
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of a new lente insulin on diabetics.
    Ohneda A; Nihei J; Sasaki M
    Diabetes Res Clin Pract; 1990 Jan; 8(2):101-7. PubMed ID: 2307090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ultratard HM, a new human insulin. Advantages as compared to current preparations?].
    Saner B; Fankhauser S
    Schweiz Med Wochenschr; 1986 Jan; 116(4):116-9. PubMed ID: 3513303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of morning hyperglycaemia: determinants of fasting blood glucose concentrations in insulin-treated diabetics.
    Francis AJ; Home PD; Walford S; Alberti KG; Mann N; Reeves WG
    Diabet Med; 1985 Mar; 2(2):89-94. PubMed ID: 2952408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of twice daily regimens of Actrapid and Monotard insulins.
    Akintewe TA
    East Afr Med J; 1985 Mar; 62(3):196-9. PubMed ID: 3893969
    [No Abstract]   [Full Text] [Related]  

  • 32. [New formulation with improved pharmacokinetics].
    Walter M
    MMW Fortschr Med; 2015 Feb; 157(3):69. PubMed ID: 25743680
    [No Abstract]   [Full Text] [Related]  

  • 33. Diabetes: The quest for basal normoglycaemia.
    Holman RR; Turner RC
    Lancet; 1977 Feb; 1(8009):469-74. PubMed ID: 65573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine.
    Gerich J; Becker RH; Zhu R; Bolli GB
    Diabetes Technol Ther; 2006 Apr; 8(2):237-43. PubMed ID: 16734552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
    Scholtz HE; Pretorius SG; Wessels DH; Becker RH
    Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
    Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
    Kerlan V; Gouet D; Marre M; Renard É
    Ann Endocrinol (Paris); 2013 Dec; 74(5-6):487-90. PubMed ID: 23978337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A practical guide to basal and prandial insulin therapy.
    Holman RR; Turner RC
    Diabet Med; 1985 Jan; 2(1):45-53. PubMed ID: 2951066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin glargine dosing before next-day surgery: comparing three strategies.
    Rosenblatt SI; Dukatz T; Jahn R; Ramsdell C; Sakharova A; Henry M; Arndt-Mutz M; Miller V; Rogers K; Balasubramaniam M
    J Clin Anesth; 2012 Dec; 24(8):610-7. PubMed ID: 23122972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
    Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
    Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.